NDAORALTABLETPriority Review
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
24
Data completeness
7/8 — Comprehensive
Priority Review
ALUNBRIG (brigatinib) by Takeda is tyrosine kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2017.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUNBRIG (brigatinib) is an oral tyrosine kinase inhibitor approved in April 2017 for ALK-positive non-small cell lung cancer. It works by blocking ALK (anaplastic lymphoma kinase) and ROS1 signaling pathways that drive cancer cell growth. The drug is designed for patients with ALK+ NSCLC, including those resistant to prior ALK inhibitors.
$33MPart D
PeakStable
9.4 years to LOEALUNBRIG is in peak commercial phase with modest Part D spending of $33M (2023) and 1,733 claims, indicating stable but narrow market penetration within the ALK+ NSCLC space; team size likely small to moderate relative to blockbuster franchises.
Mechanism of Action
Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (24)
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
Started Jun 2024
0NSCLC, Stage IIIALK-rearrangement
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
Started Jan 2024
154 enrolled
Non-small Cell Lung Cancer (NSCLC)
A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults
Started Dec 2023
12 enrolled
Healthy Volunteers
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
Started May 2023
50 enrolled
Non-small Cell Lung Cancer (NSCLC)
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Started Aug 2022
65 enrolled
Anaplastic Large Cell Lymphoma, ALK-PositiveInflammatory Myofibroblastic TumorOther Solid Tumor
Worked on ALUNBRIG at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.